GR
Therapeutic Areas
Iterum Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sulopenem (oral) | Uncomplicated Urinary Tract Infection (uUTI) in women with quinolone-non-susceptible pathogens | Phase 3 |
| Sulopenem (IV to oral) | Complicated Urinary Tract Infection (cUTI), including acute pyelonephritis | Phase 3 |
Leadership Team at Iterum Therapeutics
CN
Corey N. Fishman
Chief Executive Officer and Director
JM
Judith M. Matthews
Interim Chief Financial Officer
MW
Michael W. Dunne, M.D.
Chief Scientific Officer
BD
Bryan D. Love
Senior Vice President, Technical Operations
WF
William F. Spengler
Chairman of the Board of Directors
DG
David G. Kelly
Director
KJ
Katherine J. Fallon
Director
DR
Daniel R. Burgess
Director